NCT00477425

Brief Summary

This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2007

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 21, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 23, 2007

Completed
9 days until next milestone

Study Start

First participant enrolled

June 1, 2007

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2007

Completed
Last Updated

May 15, 2017

Status Verified

May 1, 2017

Enrollment Period

Same day

First QC Date

May 21, 2007

Last Update Submit

May 11, 2017

Conditions

Carcinoma

Keywords

Avastin

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Signed Informed Consent Form
  • Enrollment in one of a list of certain randomized, controlled bevacizumab trials

You may not qualify if:

  • Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
  • Congenital long QT syndrome
  • Family history of long QT syndrome
  • Clinically significant bradycardia (defined as \< 50 beats/minute)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Carcinoma

Condition Hierarchy (Ancestors)

Neoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasms

Study Officials

  • Jane Huang, M.D.

    Genentech, Inc.

    STUDY DIRECTOR
0

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 21, 2007

First Posted

May 23, 2007

Study Start

June 1, 2007

Primary Completion

June 1, 2007

Study Completion

June 1, 2007

Last Updated

May 15, 2017

Record last verified: 2017-05